Fibrinolytic Activity and Protein C in Preeclampsia

Aznar, Justo; Gilabert, J.; Estellés, Amparo; España, Francisco

doi:10.1055/s-0038-1661554

Cited by 61 publications

(36 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that the t-PA antigen level increased gradually during pregnancy. As t-PA has been shown to be produced mainly by endothelial cells, this result shows that the change was caused by a change in the cardiovas cular system during pregnancy [11,12]. The u-PA antigen level is constant in nonpregnant women [13,14], but increases gradually during pregnancy, because u-PA is produced by placental tissue and because its level in creased with growth of placental tissue [11].…”

Section: Discussionmentioning

confidence: 93%

“…There are reports of increases of PAI-1 and t-PA [23,24] and a decrease of PAI-2 in severe preeclampsia [12], Moreover, the placental tissue of women with severe pre eclampsia has been found to have a lower fibrinolytic activity than that of normal pregnant women [25], In pla cental tissue, PAI-1, PAI-2, t-PA, and u-PA form com plexes that control the fibrinolytic activity, preventing adhesion of the placenta to the uterus [26], In severe pre eclampsia, the fibrinolytic activity is lower than in normal pregnancy, microthrombosis occurs in placental tissue, and vessel endothelial cells throughout the body are stim ulated. Therefore, the plasma levels of PAI-1 and t-PA increase, and the placental function for destruction of pla cental tissue decreases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Fibrinolysis during Normal Pregnancy and Severe Preeclampsia Relationships between Plasma Levels of Plasminogen Activators and Inhibitors

Nakashima

Kobayashi

Terao

1996

Gynecol Obstet Invest

View full text Add to dashboard Cite

The antigen levels of plasminogen activator inhibitor type 1 (PAI-1), plasminogen activator inhibitor type 2 (PAI-2), tissue-type plasminogen activator (t-PA), and urokinase-type plasminogen activator (u-PA) were measured during pregnancy and severe preeclampsia. The PAI-1 and PAI-2 antigen levels increased linearly during pregnancy and promptly returned to the level of non-pregnant women after delivery. The t-PA and u-PA antigen levels increased slowly and linearly during pregnancy. In severe preeclampsia, the PAI-2 antigen level was lower than that observed during the 3rd trimester of normal pregnancy, and the t-PA antigen level was higher than that during the 3rd trimester of normal pregnancy. Immunohistochemical examination of placental tissue showed that the PAI-2 and u-PA antigens were localized in syncytio-trophoblasts. In severe preeclampsia, the PAI-2 and u-PA antigens in placental tissue did not stain as clearly as during the 3rd trimester of normal pregnancy. The PAI-2 and u-PA antigen levels showed a positive correlation with birth weight. Therefore, PAI-2 may be an important marker of placental function and abnormality in pregnancies.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Fibrinolysis during Normal Pregnancy and Severe Preeclampsia Relationships between Plasma Levels of Plasminogen Activators and Inhibitors

Nakashima

Kobayashi

Terao

1996

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…These changes had often already occurred prior to the onset of clinical symptoms. In pregnancies complicated by preeclampsia, increased levels of coagulation factor VIII, von Willebrand factor, thrombin-anti-thrombin, d-dimer complex, soluble fibrin and thrombomodulin have been found [60][61][62][63][64][65] . Other confirmed changes include the activation of granulocytes and monocytes and the associated release of inflammatory cytokines 66,67 .…”

Section: Tissue Factor -Its Role During Normal Pregnancy and The Devementioning

confidence: 99%

The role of tissue factor in normal pregnancy and in the development of preeclampsia: A review

Procházková¹,

Slavík²,

Úlehlová³

et al. 2015

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Background. Tissue factor (TF) is a key element for normal gestation, especially in the first trimester. TF levels are hence raised in pregnancy, producing an adaptive hypercoagulable state. Potentiated hypercoagulability however, is associated with disorders of pregnancy such as pre-eclampsia but the results of TF and its inhibitor, tissue factor pathway inhibitor (TFPI), measurement, in pre eclampsic women are ambiguous and the data conflicting. This review covers the current knowledge status of the role of TF assessment in pregnancy with a focus on its diagnostic utility. Methods. A review of the literature using the following key words: tissue factor, thrombosis, inflammation, pregnancy, preeclampsia.Results. The published literature shows raised and unchanged TF levels in various studies of pre-eclampsia along with equally conflicting data for TFPI. The various study designs and methods used in these studies makes valid comparison difficult. Meta analysis of 34 randomized trials showed that low-dose aspirin in early phases of gravidity (starting from the 16th week or earlier) significantly reduces the incidence of preeclampsia. Conclusions. Overall, the results of the literature search together with knowledge of the structure and biological effects of TF, suggest that measuring the level of plasma TF/TFPI is not ideal for determining the actual levels of TF in the uteroplacental circulation. The current view that endothelial dysfunction is the trigger for preeclampsia, suggests that aspirin may be an effective prophylaxis. Further research will be necessary: measuring the expression of tissue factor on monocytes using flowcytometry and comparing the development of this expression during normal pregnancy and pregnancy complicated by preeclampsia, for example. Another possibility is immunohistochemical determination of the level of TF expression directly in placental tissue.

show abstract

“…More recent studies show that the plasminogen activator inhibitor also steadily increases throughout pregnancy (13,14), whereas a special elevation is seen in pre-eclampsia (15,16). Recently several new tests became available both for the investigation of coagulation activation and for the assessment of the level of fibrinolytic parameters.…”

Section: Introductionmentioning

confidence: 99%

Blood Coagulation and Fibrinolysis During Normal Pregnancy

Wersch¹,

Ubachs²

1991

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Summary: Fifty-six pregnant women (gestational age 6-40 weeks) were evaluated for their coagulation activation (fibrin monomers and thrombin-antithrombin III complex) and for their fibrinolysis profile by determining tissue plasminogen activator, plasminogen activator inhibitor, plasminogen, a 2 -antiplasmin-and D-dimer. Fibrin monomers and thrombin-antithrombin III complexes were found to be significantly increasing with gestational age. All the fibrinolytic parameters showed a steady growth with the progress of the pregnancy, with the exception of tissue plasminogen activator which showed a significant decrease with gestational age, but mainly within the reference ränge. These results suggest a Stimulation of the coagulation System and an activation of fibrinolysis with ongoing pregnancy, although the increasing oc 2 -antiplasmin and plasminogen levels and the decreasing tissue plasminogen activator concentrations do not conform to this trend.

show abstract

Fibrinolytic Activity and Protein C in Preeclampsia

Cited by 61 publications

References 29 publications

Fibrinolysis during Normal Pregnancy and Severe Preeclampsia Relationships between Plasma Levels of Plasminogen Activators and Inhibitors

Fibrinolysis during Normal Pregnancy and Severe Preeclampsia Relationships between Plasma Levels of Plasminogen Activators and Inhibitors

The role of tissue factor in normal pregnancy and in the development of preeclampsia: A review

Blood Coagulation and Fibrinolysis During Normal Pregnancy

Contact Info

Product

Resources

About